Who is sponsoring NCT03505866?

NCT03505866 is sponsored by Integrated Development Foundation Nepal.

What drugs are being tested in NCT03505866?

Interventions in NCT03505866: Community home-based care intervention.

What condition does NCT03505866 study?

NCT03505866 studies Human Immunodeficiency Virus, Depression, Stress, Anxiety, Quality of Life.

Is NCT03505866 still recruiting?

NCT03505866 is currently completed. Last updated 24 April 2018.

Last reviewed 2018-04-24 · How we verify

NCT03505866: HIV

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Community Home-based Care Intervention and Its Health Outcome in HIV-positive People

Completed NA Last updated 24 April 2018

What this trial tests

NA trial testing Community home-based care intervention in Human Immunodeficiency Virus in 720 participants. Completed in 31 August 2015.

Timeline

1 March 2015

Primary endpoint
31 August 2015

31 August 2015

Quick facts

Lead sponsor	Integrated Development Foundation Nepal
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	720
Start date	1 March 2015
Primary completion	31 August 2015
Estimated completion	31 August 2015

Drugs / interventions tested

Community home-based care intervention

Conditions studied

Human Immunodeficiency Virus — all drugs for Human Immunodeficiency Virus →
Depression — all drugs for Depression →
Stress — all drugs for Stress →
Anxiety — all drugs for Anxiety →

Sponsor

Integrated Development Foundation Nepal

Who can join

18 and older, any sex, with Human Immunodeficiency Virus or Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An intervention study was designed to examine the impact of impact of community home-based care intervention on mental health and treatment outcome in HIV-positive people. The intervention comprised a home-based counseling on anti-retroviral therapy (ART) adherence, psycho social support, basic health care services at the home of HIV-positive people. The intervention started in March, 2018 and completed in August 2018. The major measurements of the interventions were ART adherence, status of depression, anxiety, and stress levels.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Investigating the impact of a community home-based care on mental health and anti-retroviral therapy adherence in people living with HIV in Nepal: a community intervention study.
Pokhrel KN, Sharma VD, Pokhrel KG, Neupane SR, et al · · 2018 · cited 14× · PMID 29879916 · DOI 10.1186/s12879-018-3170-1

Verify or expand the search:

Other recruiting trials for Human Immunodeficiency Virus

Currently open trials in the same condition.

NCT07530198 — HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong · Phase 1 · recruiting
NCT06819176 — Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretrovir · Phase 1 · recruiting
NCT06408142 — Universal Test and Connect for HIV Service Delivery in South Africa · recruiting
NCT07101458 — The Eswatini PRISM Study on Adolescents Living With HIV · NA · recruiting
NCT06554223 — The SUSTAIN 2 Study - SUStained HIV Treatment for Adherence After Interruption in Care · NA · recruiting

Other Integrated Development Foundation Nepal trials

Trials by the same sponsor.

NCT06213207 — Cluster Randomized Controlled Trial Applying Helping Baby Breathe in Nepal · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03505866 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Integrated Development Foundation Nepal
Last refreshed: 24 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03505866.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing